| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||
| Sponsors and Collaborators: |
National Center for Research Resources (NCRR) Crohn's and Colitis Foundation |
| Information provided by: | National Center for Research Resources (NCRR) |
| ClinicalTrials.gov Identifier: | NCT00035074 |
Purpose
Patients with inflammatory bowel disease (IBD) who require methotrexate (MTX)for treatment currently receive this drug by injection. MTX is also available as a pill that can be given by mouth but it is not known how well the drug enters the body in patients with Crohn's disease or ulcerative colitis. This study is being done to compare how much MTX enters the body when the drug is taken by mouth compared to when it is given by injection. If the drug is well absorbed, it may allow patients to receive the drug by mouth.
| Condition | Intervention |
|
Inflammatory Bowel Disease |
Drug: Methotrexate |
| Genetics Home Reference related topics: | Crohn disease |
| ChemIDplus related topics: | Methotrexate |
| Study Type: | Interventional |
| Study Design: | Treatment, Crossover Assignment, Bio-availability Study |
| Official Title: | A Pharmacokinetic Study to Determine the Oral Bioavailability of Methotrexate in Patients With Inflammatory Bowel Disease |
Eligibility
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Contacts and Locations| United States, Pennsylvania | |||||
| Childrens Hospital of Philadelphia | |||||
| Philadelphia, Pennsylvania, United States, 19104 | |||||
| National Center for Research Resources (NCRR) |
| Crohn's and Colitis Foundation |
More Information
| Study ID Numbers: | NCRR-M01RR00240-1757 |
| First Received: | May 2, 2002 |
| Last Updated: | June 23, 2005 |
| ClinicalTrials.gov Identifier: | NCT00035074 |
| Health Authority: | United States: Federal Government |
|
|
|
|
|
